FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086348570> ?p ?o ?g. }

• W2086348570 endingPage "373" @default.
• W2086348570 startingPage "358" @default.
• W2086348570 abstract "Cardiovascular Drug ReviewsVolume 17, Issue 4 p. 358-373 Free Access Cardiovascular Effects of Octreotide, a Long-Acting Somatostatin Analog Hironosuke Sakamoto, Corresponding Author Hironosuke Sakamoto The Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, JapanAddress correspondence and reprint requests to Dr. Hironosuke Sakamoto, Cardiovascular Division, Brigham and Women's Hospital, Thorn Building, Rm. 1327, 75 Francis Street, Boston, MA 02115. Fax: (617)-582-6069;E-mail: hsakamoto@rics.bwh.harvard.edu.Search for more papers by this author Hironosuke Sakamoto, Corresponding Author Hironosuke Sakamoto The Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, JapanAddress correspondence and reprint requests to Dr. Hironosuke Sakamoto, Cardiovascular Division, Brigham and Women's Hospital, Thorn Building, Rm. 1327, 75 Francis Street, Boston, MA 02115. Fax: (617)-582-6069;E-mail: hsakamoto@rics.bwh.harvard.edu.Search for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3466.1999.tb00025.xCitations: 3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Albat B, Leclercq FF, Serre I, et al. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J 1993; 14: 1572– 1575. 2 Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369– 375. 3 Bauer W, Briner U, Doepfner W, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31: 1133– 1140. 4 Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 173: 77– 79. 5 Buscail L, Delesque N, Esteve J-P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 2315– 2319. 6 Cao K, Grunstein RR, Ho KY, Sullivan CE. The effect of octreotide on breathing and the ventilatory response to CO2 in conscious dogs. Eur Respir J 1988; 11: 1376– 1381. 7 Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113: 921– 925. 8 Cohen P. Signal integration at the level of protein kinases, protein phosphatases, and their substrates. Trends Biochem Sci 1992; 17: 408– 413. 9 Colao A, Cuocolo A, Marzullo P, et al. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17– 23. 10 Cool DE, Andreassen PR, Tonks NK, Krebs EG, Fischer FH, Morgolis RL. Cytokinetic failure and asynchronous nuclear division in BHK cells overexpressing a truncated protein-tyrosine-phosphatase. Proc Natl Acad Sci USA. 1992; 89: 5422– 5426. 11 del Pozo E, Neufeld M, Schluter K, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 1986; 111: 433– 439. 12 Demirtas E, Sag C, Kursaklioglu H, et al. Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy. Jpn Heart J 1998; 39: 173– 181. 13 Fallo F, Barzon L, Boscaro M, Casiglia E, Sonino N. Effect of octreotide on 24-h blood pressure profile in acromegaly. Am J Hypertens 1998; 11: 591– 596. 14 Filuk RB, Berezanski DJ, Anthonisen NR. Depression of hypoxic ventilatory response in humans by somatostatin. J Appl Physiol 1988; 65: 1050– 1054. 15 Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995; 80: 3601– 3607. 16 Fuessl HS, Burrin JM, Williams G, Adrian TE, Bloom SR. The effect of a long-acting somatostatin analogue (SMS 201–995) on intermediary metabolism and gut hormones after atest meal in normal subjects. Aliment Pharmacol Ther 1987; 1: 321– 330. 17 Gaudin C, Moreau R, Champigneulle B, Soubrane O, Kleber G, Lebrec D. Short-term cardiovascular effects of somatostatin in patients with cirrhosis. Liver 1995; 15: 236– 241. 18 Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). Drug 1997; 53: 681– 699. 19 Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis Circulation 1994; 89: 1511– 1517. 20 Grunstein RR, Ho KY, Berthon-Jones M, Stewart D, Sullivan CE. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly. Am J Respir Crit Care Med 1994; 150: 496– 502. 21 Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115: 527– 532. 22 Grunstein RR, Ho KY, Sullivan CE. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994; 121: 478– 83. 23 Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 1994; 35(Suppl 3): S1– S4. 24 Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomie neuropathy. Circulation 1991; 84: 168– 176. 25 Hoeldtke RD, O'Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201–995. Lancet 1986; 2: 602– 605. 26 Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715– 1721. 27 Jones CR, Millar JA, Lawrie C, Summer DJ, Reid JL. Specific inhibition of aldosterone response to endogenous and exogenous angiotensin II by somatostatin. Clin Endocrinol 1984; 21: 279– 284. 28 Kobayashi S, Nishimura M, Taguchi H, Miyamoto K, Kawakami Y. Effect of octreotide on ventilation and dyspnea sensation in a patient with cirrhotic hypoxemia. Intern Med 1995; 34: 401– 405. 29 Kutz K, Nuesch E, Rosenthaler J. Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol 1986; 21(Suppl 119): 65– 72. 30 Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60: 1161– 1165. 31 Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A, Maurer G. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. Drug Metab Dispos 1989; 17: 699– 703. 32 Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201–995) on gastrointestinal, pancreatic, and biliary function and hormone release in normal man. Digestion 1987; 36: 108– 124. 33 Lim MJ, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypertension. Ann Intern Med 1992; 117: 719– 726. 34 Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106– 113. 35 Liu MW, Roubin GS, King SB, III Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989; 79: 1374– 1387. 36 Londong W, Angerer M, Kutz K, Landgraf R, Londong V. Diminishing efficacy of octreotide (SMS 201–995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989; 96: 713– 722. 37 Malesci A, Tacconi M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1997; 26: 816– 825. 38 Maxwell DL, Chahal P, Nolop KB, Hughes JM. Somatostatin inhibits the ventilatory response to hypoxia in humans. J Appl Physiol 1986; 60: 997– 1002. 39 McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology 1995; 21: 1255– 1260. 40 Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, Karvountzis G, Tolis G. Enhancement of renal function by a long acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant 1988; 3: 604– 607. 41 Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616– 623. 42 Padayatty S, Perrins EJ, Belchetz PE. Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol 1996; 134: 554– 559. 43 Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995; 57: 1249– 1265. 44 Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495– 1501, 1556–1563. 45 Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 1995; 16: 427– 442. 46 Reubi JC, Lamberts SWJ, Maurer R. Somatostatin receptors in normal and tumoral tissues. Horm Res 1988; 29: 65– 69. 47 Reubi JC, Maurer R, von Werder K, Torhoest J, Klijn KGM, Lamberts SWJ. Somatostatin receptors in human endocrine tumors. Cancer Res 1987; 47: 551– 558. 48 Rodriguez-Perez F, Albillos A, Groszman RL. Octreotide improves renal function, total exchangeable sodium, and peripheral hemodynamics in cirrhotic patients with ascites. Gastroenterology 1993; 104: 980A. (Abstract). 49 Ross R. The pathogenesis of atherosclerosis. An update. N Engl J Med 1986; 314: 488– 500. 50 Sabat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998; 43: 2184– 2189. 51 Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555– 573. 52 Sakamoto H, Sakamaki T, Kanda T, et al. The somatostatin analog, octreotide, inhibits in vitro outgrowth of smooth muscle cells from canine coronary and carotid atherosclerotic plaque tissues. Res Commun Mol Pathol Pharmacol 1998; 101: 25– 34. 53 Schwartz RS, Topol EJ, Serruys PW, Sangiori G, Holmes DR. Artery size, neointima, and remodeling. Time for some standards. J Am Coll Cardiol 1998; 31: 2087– 2094. 54 Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979; 48: 50– 53. 55 Sieber C, Gnadinger M, del Pozo E, Shaw S, Weidmann P. Effect of a new somatostatin analogue SMS 201–995 (Sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988; 28: 25– 32. 56 Srikant CB, Shen SH. Octreotide somatostatin analog SMS 201–995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 1996; 137: 3461– 3468. 57 Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80: 3267– 3272. 58 Tokgozoglu SL, Erbas T, Aytemir K, Akalin S, Kes S, Oram E. Effects of octreotide on left ventricular mass in acromegaly. Am J Cardiol 1994; 74: 1072– 1074. 59 von Essen R, Ostermaier R, Grube E, et al., for the VERAS Investigators. Effects of octreotide treatment on restenosis after coronary angioplasty. Results of the VERAS study. Circulation 1997; 96: 1482– 1487. 60 Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988; 57: 443– 478. 61 Yumi K, Fagin JA, Yamashita M, et al. Direct effects of somatostatin analog octreotide on insulin-like growth factor-I in the arterial wall. Lab Invest 1997; 76: 329– 338. Citing Literature Volume17, Issue4December 1999Pages 358-373 ReferencesRelatedInformation" @default.
• W2086348570 created "2016-06-24" @default.
• W2086348570 creator A5029973588 @default.
• W2086348570 date "2006-06-07" @default.
• W2086348570 modified "2023-09-23" @default.
• W2086348570 title "Cardiovascular Effects of Octreotide, a Long-Acting Somatostatin Analog" @default.
• W2086348570 cites W1969311477 @default.
• W2086348570 cites W1970939090 @default.
• W2086348570 cites W1971820086 @default.
• W2086348570 cites W1972467246 @default.
• W2086348570 cites W1981547344 @default.
• W2086348570 cites W1984572394 @default.
• W2086348570 cites W1992639178 @default.
• W2086348570 cites W1995512164 @default.
• W2086348570 cites W1997833101 @default.
• W2086348570 cites W1998933514 @default.
• W2086348570 cites W2002087040 @default.
• W2086348570 cites W2004174160 @default.
• W2086348570 cites W2005518939 @default.
• W2086348570 cites W2006611896 @default.
• W2086348570 cites W2006769040 @default.
• W2086348570 cites W2009318088 @default.
• W2086348570 cites W2015932636 @default.
• W2086348570 cites W2026204848 @default.
• W2086348570 cites W2026581670 @default.
• W2086348570 cites W2035147290 @default.
• W2086348570 cites W2036071094 @default.
• W2086348570 cites W2036716935 @default.
• W2086348570 cites W2040540478 @default.
• W2086348570 cites W2041819693 @default.
• W2086348570 cites W2043750439 @default.
• W2086348570 cites W2047702417 @default.
• W2086348570 cites W2051340869 @default.
• W2086348570 cites W2051904824 @default.
• W2086348570 cites W2055402549 @default.
• W2086348570 cites W2055481572 @default.
• W2086348570 cites W2056170470 @default.
• W2086348570 cites W2061755142 @default.
• W2086348570 cites W2066485992 @default.
• W2086348570 cites W2066524003 @default.
• W2086348570 cites W2067794530 @default.
• W2086348570 cites W2071310612 @default.
• W2086348570 cites W2072835375 @default.
• W2086348570 cites W2075910471 @default.
• W2086348570 cites W2077916008 @default.
• W2086348570 cites W2081461681 @default.
• W2086348570 cites W2083522090 @default.
• W2086348570 cites W2085864058 @default.
• W2086348570 cites W2103174300 @default.
• W2086348570 cites W2142589961 @default.
• W2086348570 cites W2144606105 @default.
• W2086348570 cites W2160793192 @default.
• W2086348570 cites W2171691652 @default.
• W2086348570 cites W2201798686 @default.
• W2086348570 cites W2344092495 @default.
• W2086348570 cites W2460847725 @default.
• W2086348570 cites W288110886 @default.
• W2086348570 cites W4239520211 @default.
• W2086348570 cites W4249967383 @default.
• W2086348570 doi "https://doi.org/10.1111/j.1527-3466.1999.tb00025.x" @default.
• W2086348570 hasPublicationYear "2006" @default.
• W2086348570 type Work @default.
• W2086348570 sameAs 2086348570 @default.
• W2086348570 citedByCount "4" @default.
• W2086348570 countsByYear W20863485702015 @default.
• W2086348570 countsByYear W20863485702019 @default.
• W2086348570 countsByYear W20863485702023 @default.
• W2086348570 crossrefType "journal-article" @default.
• W2086348570 hasAuthorship W2086348570A5029973588 @default.
• W2086348570 hasBestOaLocation W20863485701 @default.
• W2086348570 hasConcept C126322002 @default.
• W2086348570 hasConcept C134018914 @default.
• W2086348570 hasConcept C2776297358 @default.
• W2086348570 hasConcept C2781025020 @default.
• W2086348570 hasConcept C2910487530 @default.
• W2086348570 hasConcept C71924100 @default.
• W2086348570 hasConceptScore W2086348570C126322002 @default.
• W2086348570 hasConceptScore W2086348570C134018914 @default.
• W2086348570 hasConceptScore W2086348570C2776297358 @default.
• W2086348570 hasConceptScore W2086348570C2781025020 @default.
• W2086348570 hasConceptScore W2086348570C2910487530 @default.
• W2086348570 hasConceptScore W2086348570C71924100 @default.
• W2086348570 hasIssue "4" @default.
• W2086348570 hasLocation W20863485701 @default.
• W2086348570 hasOpenAccess W2086348570 @default.
• W2086348570 hasPrimaryLocation W20863485701 @default.
• W2086348570 hasRelatedWork W1982345662 @default.
• W2086348570 hasRelatedWork W2013777072 @default.
• W2086348570 hasRelatedWork W2039503182 @default.
• W2086348570 hasRelatedWork W2124342755 @default.
• W2086348570 hasRelatedWork W2131979641 @default.
• W2086348570 hasRelatedWork W2145971304 @default.
• W2086348570 hasRelatedWork W2148426378 @default.
• W2086348570 hasRelatedWork W2151397963 @default.
• W2086348570 hasRelatedWork W2335272111 @default.
• W2086348570 hasRelatedWork W2014450888 @default.
• W2086348570 hasVolume "17" @default.
• W2086348570 isParatext "false" @default.

• next